Mujahed Abbas, MD
Critical Care Medicine · Lansing, MINPI 1861500894
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,556 of the $27,902 with a category attached, or 77.3%. Melinta Therapeutics, LLC accounts for 89.7% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $10,240 and has fallen 94.0% since, to $619 in 2025. Among critical care medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $98.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Melinta Therapeutics, LLC$25K
- Insmed, Inc.$1K
- Gilead$558
- Viiv Healthcare Company$302
- Paratek Pharmaceuticals, Inc.$205
- Merck$158
- plus $628 from 11 others
What the payments were for
- Consulting fees$7503%
- Speaking & faculty fees$21,55677%
- Travel & lodging$1,2344%
- Food & beverage$4,03514%
- Education$3281%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Melinta Therapeutics, LLC | 124 | $25,039 |
| Insmed, Inc. | 57 | $1,013 |
| Gilead | 30 | $558 |
| Viiv Healthcare Company | 22 | $302 |
| Paratek Pharmaceuticals, Inc. | 10 | $205 |
| Merck | 9 | $158 |
| Biofire Diagnostics, LLC | 1 | $138 |
| La Jolla Pharmaceutical Company | 8 | $117 |
| Ferring Pharmaceuticals Inc. | 4 | $92 |
| Tetraphase Pharmaceuticals, Inc. | 5 | $75 |
| AbbVie(2 entities) | 4 | $64 |
| Shionogi Inc | 2 | $37 |
| Johnson & Johnson | 2 | $29 |
| Grifols USA, LLC | 1 | $22 |
| Mayne Pharma Commercial LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $19 |
| Nabriva Therapeutics, PLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kimyrsa$13,325
- Rezzayo$10,190
- Film Array System$138
How this compares
$27,902 in reported general payments places this provider in the 95th percentile of 177 critical care medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $49,669 |
| ErtapenemErtapenem Sodium | 35 | $16,773 |
| Daptomycin | 42 | $13,400 |
| Vancomycin Hcl | 72 | $7,659 |
| Itraconazole | 23 | $5,683 |
| CeftriaxoneCeftriaxone Sodium | 109 | $5,252 |
| Cefepime Hcl | 36 | $5,151 |
| Ampicillin Sodium | 16 | $3,955 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 16 | $2,940 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 35 | $1,483 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 54 | $1,321 |
| Cephalexin | 32 | $779 |
| Cefazolin Sodium | 29 | $734 |
| Fluconazole | 11 | $617 |
| Linezolid | 12 | $305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $558 | $49,66912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 critical care medicine providers in Michigan.
Other critical care medicine in Lansing
- Angel Peralta-AvilaDetroit$147K
- Moumen AsbahiTroy$81K
- Abdulrazak AlchakakiSouthfield$19K
- Narayana GandhamSaint Joseph$18K
- Sara MirzaAnn Arbor$12K
- Asker AsmiRiverview$11K
- Andrew EasowDearborn$10K
- Jeffery WiltGrand Rapids$10K
- Furqan SiddiqiSaint Joseph$8K
- Amin PashaDetroit$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.